Effects of hyperbaric oxygen combined with selegiline on motor function, serum miR-124, and IGF-1 in patients with Parkinson′s disease
10.3760/cma.j.cn311847-20191018-00271
- VernacularTitle:高压氧联合司来吉兰对帕金森病患者运动功能及血清miR-124、IGF-1水平的影响
- Author:
Yumin CHEN
1
;
Xuan ZHANG
;
Qingyan FENG
;
Bingwang YAN
;
Jingjing WEI
;
Liying ZHAO
;
Wenting ZHAO
;
Xinyan YI
Author Information
1. 272000 山东省济宁，济宁市第一人民医院神经内科
- Publication Type:Journal Article
- Keywords:
Parkinson′s disease;
Hyperbaric oxygen;
Selegiline;
MicroRNA-124;
Insulin-like growth factor-1
- From:
Chinese journal of nautical medicine and hyperbaric medicine
2020;27(2):200-204
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of hyperbaric oxygen (HBO) combined with selegiline on motor function, serum microRNA-124 (miR-124), insulin-like growth factor-1 (IGF-1) in patients with Parkinson′s disease (PD).Methods:A total of 120 PD patients, admitted in the Department of Neurology of Jining No.1 People′s Hospital from the March of 2017 to the March of 2019, were selected and divided into control group and HBO group according to the random number table method with each group consisting of 60 patients. The patients in the control group received levodopa and selegiline treatment, while the patients of HBO group were treated with HBO combined with the same medication of the control group. After three courses of treatment, clinical symptoms of the two groups were observed; motor function was assessed by the unified Parkinson′s disease rating scale (UPDRS); non-motor function was assessed by the PD non-motor symptom questionnaire (NMSQuest) and the Parkinson′s disease sleep scale (PDSS); the levels of serum oxidative stress index, inflammatory factor, IGF-1 and miR-124 before and after treatment were compared.Results:After 30 d treatment, the incidences of mental disorders, sensory disturbances, autonomic nervous dysfunction and sleep disorders of the two groups were significantly lower than those before treatment, and those of HBO group after treatment were significantly lower than those of the control group ( P<0.01). The UPDRS II and UPDRS III scores of both groups after treatment were significantly lower than those before treatment ( P<0.05). The UPDRS II and UPDRS III scores of the HBO group after treatment were significantly lower than those of the control group ( P<0.05 or P<0.01). Compared with those before treatment, the NMSQuest score of both two groups decreased and the PDSS score of both two groups increased. After treatment, the NMSQuest score of the HBO group was significantly lower than that of the control group; while the PDSS score of the HBO group was significantly higher than that of the control group ( P<0.05 or P<0.01). Compared with those before treatment, the levels of hs-CRP, IL-6, and MDA of the HBO group were significantly lower than those of the control group, while the SOD was significantly higher than that of the control group ( P<0.05). After treatment, the relative quantitative expressions of miR-124 and the levels of IGF-1 of both two groups were significantly higher than those before treatment, and the relative quantitative expressions of miR-124 and the levels of IGF-1 of the HBO group was significantly higher than those of the control group ( P<0.05 or P<0.01). Conclusion:HBO combined with selegiline can significantly improve the oxidative stress disorder in PD patients, promote the expressions of miR-124 and IGF-1, strengthen neuroprotective effects, and significantly improve motor function and non-motor disorders, so as to improve the therapeutic effect.
